Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
The Ministry of Health, Labor and Welfare (MHLW) handed out regulatory approvals for a slew of new medicines and indications on March 27, with four novel cancer therapies among them including Janssen Pharmaceutical’s (J&J) Lazcluze (lazertinib). Lazcluze, a third-generation oral…
To read the full story
Related Article
- Chuikyo OKs Listing of Tevimbra, Camzyos, Tremfya, and More
May 15, 2025
- Label Updated for Eliquis, Imbruvica, and Brimonidine: PMDA
March 31, 2025
- MHLW Flags Risk of Eye Disorders Associated with Tivdak upon Approval
March 31, 2025
- Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
- J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
REGULATORY
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
- LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…